Oral IPH-AGAA and muscle measures in an uncontrolled human report
Ideal Pharma Peptide · 2019 · Ideal Pharma Peptide clinical study report
Published 2019-08-13. Indexed 2026-11-13.
Related evidence maps: Military & occupational research ↗
Reported findings and study design
The company reported dynamometry readings at 1.2 times baseline and bioimpedance-estimated muscle mass at 1.1 times baseline in the 100 µg series.
Before-and-after assessments at 3 and 6 months used self-rating scales, Omron bioimpedance and dynamometry. Participants were advised to exercise. There was no placebo arm.
Dose, route and schedule
One oral capsule with 100 µg IPH-AGAA daily for three 30-day courses, each followed by a 30-day break over six months. The report also describes 50 and 150 µg dose series.
Protocol source ↗ · Manufacturer report, methods and results text
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Dynamometry | 1.2 times baseline | Company-reported within-group change in the 100 µg series. |
| Body composition by bioimpedance | Muscle mass at 1.1 times baseline and fat mass at about 0.77 times baseline | Company-reported ratios relative to baseline. The report describes a 1.3-fold reduction in fat mass. |
| Self-rated activity, energy and endurance | 1.5 times baseline at 3 months | Reported as stable through month 6. |
| Dose comparisons | No significant differences reported between 100 and 150 µg | The 50 µg series had no significant change from baseline according to the report. |
These before-and-after observations cannot establish efficacy or determine an optimal dose.
Source for these results ↗ · Reviewed 2026-11-13
For research and education. Consult a qualified clinician for medical advice.
Study limitations and source details
Study limitations
- The report does not establish randomization, masking, a placebo comparison or how the dose-series samples were assembled.
- Exercise, measurement variability and time may contribute to the changes. Systematic adverse-event monitoring is not described.
Available format: Manufacturer report, methods and results text
Material reviewed: Reported methods, results and evidence limitations
Source access
Manufacturer report, methods and results text
Source reviewed 2026-11-13.
Source type: Manufacturer report
Citation and original source
Original source: Ideal Pharma Peptide. Oral IPH-AGAA and muscle measures in an uncontrolled human report Ideal Pharma Peptide clinical study report 2019.
Molekul research summary: https://molekul.io/research/iph-agaa-muscle-function-2019. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry